PetIQ, Inc. (PETQ) Stock Analysis

PetIQ, Inc. (PETQ) Healthcare & Pipeline Overview

PetIQ, Inc. is a pet medication and wellness company that operates in the United States and internationally, providing a diverse range of products and services, including prescription and over-the-counter medications, health and wellness products, and veterinary services through community clinics, serving a broad market through various distribution channels.

What Is the Investment Thesis for PETQ?

PetIQ, Inc. presents an interesting investment case within the pet health market. The company's dual approach, offering both products and services, allows for diversified revenue streams. The expansion of community clinics and wellness centers could drive revenue growth, particularly as pet ownership continues to rise. The company's focus on value-branded products may appeal to cost-conscious consumers, potentially increasing market share. However, the company's relatively low profit margin of 0.2% and high P/E ratio of 423.80 warrant careful consideration. Upcoming expansion of veterinary services and potential partnerships with major retailers could serve as catalysts. Potential risks include increased competition in the pet medication market and fluctuations in consumer spending.

Based on FMP financials and quantitative analysis

PETQ Key Highlights

Market Cap of $919M reflects investor valuation of PetIQ's growth potential in the pet medication and wellness market.

• P/E Ratio of 423.80 suggests that the company's stock is trading at a high premium relative to its earnings.
• Gross Margin of 22.9% indicates the percentage of revenue exceeding the cost of goods sold, reflecting the company's pricing strategy and production costs.
• The company operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels, indicating a broad market reach.
• The company offers a suite of services at 2,900 community clinics and wellness centers hosted at pet retailers across 42 states, indicating a significant service footprint.

Who Are PETQ's Competitors?

PETQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PETQ's Key Strengths?

Wide range of pet medications and wellness products.

• Extensive distribution network.
• Growing network of community clinics.
• Value-branded products appeal to cost-conscious consumers.

What Are PETQ's Weaknesses?

Low profit margin.

• High P/E ratio.
• Reliance on third-party branded medications.
• Limited international presence.

What Could Drive PETQ Stock Higher?

Expansion of community clinics and wellness centers to new locations.

• Development and launch of new proprietary value-branded products.
• Strategic partnerships with major retailers to expand distribution network.

What Are the Key Risks for PETQ?

Rich valuation — a P/E of 423.80 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $1.9M recently.
• Increased competition in the pet medication market.
• Fluctuations in consumer spending on pet care products and services.
• Regulatory changes impacting the pet health industry.
• Supply chain disruptions affecting product availability and costs.

What Are the Growth Opportunities for PETQ?

• Expansion of Veterinary Services: PetIQ has the opportunity to expand its network of community clinics and wellness centers. With 2,900 locations across 42 states, there is room to increase the number of clinics and expand into new geographic markets. This expansion can drive revenue growth by offering accessible and affordable veterinary services, including vaccinations, diagnostic tests, and prescription medications. The market for veterinary services is estimated to be worth billions of dollars annually, and PetIQ can capture a larger share of this market by increasing its service footprint.
• Development of Proprietary Products: PetIQ can invest in the development and marketing of its own proprietary value-branded products. By creating unique and differentiated products, the company can increase its brand recognition and customer loyalty. This can also improve profit margins by reducing reliance on third-party branded medications. The market for pet health and wellness products is constantly evolving, with new products and formulations being introduced regularly. PetIQ can capitalize on this trend by developing innovative products that meet the changing needs of pet owners.
• Strategic Partnerships: PetIQ can pursue strategic partnerships with major retailers to expand its distribution network and reach new customers. By partnering with large retail chains, the company can increase the visibility of its products and services and gain access to a wider customer base. These partnerships can also provide opportunities for co-marketing and cross-promotion. The retail channel is a significant driver of sales for pet medications and wellness products, and PetIQ can leverage partnerships to increase its market share.
• E-commerce Expansion: PetIQ can further develop its e-commerce platform to increase online sales. With the growing trend of online shopping, PetIQ can capitalize on this trend by offering a convenient and user-friendly online shopping experience. This can also allow the company to reach customers in geographic areas where it does not have a physical presence. The e-commerce channel is becoming increasingly important for pet medications and wellness products, and PetIQ can invest in its online capabilities to drive growth.
• International Expansion: PetIQ can explore opportunities for international expansion to diversify its revenue streams and reduce its reliance on the U.S. market. By expanding into new international markets, the company can tap into new customer bases and increase its overall sales. This expansion can be achieved through partnerships, acquisitions, or organic growth. The global pet care market is growing rapidly, and PetIQ can capitalize on this trend by expanding its international presence.

What Are PETQ's Competitive Advantages?

• Value-branded products offer a cost advantage.
• Extensive distribution network across multiple channels.
• Community clinics provide accessible veterinary services.
• Established brand recognition with brands like PetArmor and VetIQ.

What Does PETQ Do?

PetIQ, Inc., founded in 2010 and headquartered in Eagle, Idaho, operates as a pet medication and wellness company both in the United States and internationally. The company functions through two primary segments: Products and Services. The Products segment focuses on Rx pet medications, including treatments for flea and tick control, heartworm prevention, arthritis, thyroid issues, diabetes, pain management, and antibiotics, alongside specialty medications. PetIQ develops and manufactures its own value-branded products and distributes third-party medications. The company also provides OTC medications and supplies, primarily within the flea and tick control and behavior management categories. These products are available in various forms, such as spot-on treatments, chewables, oral tablets, and collars. The Services segment offers a suite of veterinary services at approximately 2,900 community clinics and wellness centers hosted at pet retailers across 42 states. These services include diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. PetIQ's products are marketed under brands like PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles. The company distributes its products through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels.

What Products and Services Does PETQ Offer?

• Develops and manufactures proprietary value-branded pet medications.
• Distributes third-party branded pet medications.
• Offers over-the-counter (OTC) medications and supplies for pets.
• Provides health and wellness products, including dental treats and nutritional supplements.
• Operates community clinics and wellness centers at pet retailers.
• Offers veterinary services such as diagnostic tests, vaccinations, and prescription medications.
• Distributes products through veterinarian, retail, and e-commerce channels.

How Does PETQ Make Money?

• Sells prescription (Rx) pet medications, including flea and tick control and heartworm preventatives.
• Generates revenue from over-the-counter (OTC) medications and supplies.
• Provides veterinary services at community clinics and wellness centers.
• Distributes products through a network of retail, veterinary, and e-commerce channels.

What Industry Does PETQ Operate In?

PetIQ, Inc. operates within the growing pet care industry, which has seen increased demand for pet medications, wellness products, and veterinary services. The market is driven by rising pet ownership and increased spending on pet health. Competition includes established pharmaceutical companies, generic drug manufacturers, and veterinary service providers. PetIQ's strategy of offering value-branded products and accessible veterinary services positions it to capture a segment of the market focused on affordability and convenience. The pet medication market is expected to continue growing, driven by advancements in veterinary medicine and increasing awareness of pet health issues.

Who Are PETQ's Key Customers?

• Pet owners seeking affordable medications and wellness products.
• Pet owners seeking convenient veterinary services.
• Retail partners hosting PetIQ's community clinics.
• Veterinarians who distribute PetIQ's products.

Company Profile

PetIQ, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Eagle, US. The company is led by CEO McCord Christensen. PETQ has traded publicly since 2017.

Return on equity for PetIQ, Inc. stands at 1.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.2%, showing how much profit it generates from its asset base. PETQ trades at a trailing price-to-earnings ratio of 423.80, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.27 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.2%, the inverse of the P/E and a quick read on earnings relative to price.

PETQ Valuation & Market Position

With a $919M market cap, PetIQ, Inc. sits in the small-cap segment of the market.

Quarterly Financial Performance: PetIQ, Inc.

Revenue for PetIQ, Inc. came in at $328.9M during Jun 2024, a 6.6% improvement versus the preceding quarter. The company recorded net income of $15.3M, with diluted EPS of $0.44.

PetIQ, Inc.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.51 places it in the grey zone, a middle ground that warrants monitoring.

PetIQ, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 318.1% above estimates on average.

Wall Street analysts project PetIQ, Inc. revenue of about $1.31B for fiscal 2026, with EPS near $1.82.

The most recent 12 insider filings for PetIQ, Inc. break down as 12 sales and 0 purchases. On net that is roughly 142K shares disposed (about $1.9M), a signal worth weighing alongside the fundamentals.

PETQ Financials

PETQ Latest News

PETQ Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources